Antibodies specific for hyperphosphorylated tau and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12129289-B2
Application number	US-202117399205-A
Country	US
Kind code	B2
Filing date	Aug 11, 2021
Priority date	Jul 12, 2016
Publication date	Oct 29, 2024
Grant date	Oct 29, 2024

Abstract

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

First claim

What is claimed is:

1. A monoclonal antibody, or an epitope-binding fragment thereof, comprising:
(a) a Light Chain CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:40; and SEQ ID NO:46;
(b) a Light Chain CDR2 comprising the amino acid sequence of SEQ ID NO:4; SEQ ID NO:41; and SEQ ID NO:47;
(c) a Light Chain CDR3 comprising the amino acid sequence of SEQ ID NO:5; SEQ ID NO:42; and SEQ ID NO:48;
(d) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO:6; SEQ ID NO:43; SEQ ID NO:49; SEQ ID NO:52; and SEQ ID NO:55;
(e) a Heavy Chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:44; SEQ ID NO:50; SEQ ID NO:53; and SEQ ID NO:56;
and
(f) a Heavy Chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:39; SEQ ID NO:45; SEQ ID NO:51; SEQ ID NO:54; and SEQ ID NO:57.

2. The monoclonal antibody, or epitope-binding fragment thereof, according to claim 1 , wherein:
(a) the Light Chain is SEQ ID NO:12; and
(b) the Heavy Chain is selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

3. The monoclonal antibody, or epitope-binding fragment thereof, according to claim 1 , wherein:
(a) the Light Chain is selected from the group consisting of SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22 and SEQ ID NO:23; and
(b) the Heavy Chain is SEQ ID NO:11.

4. The monoclonal antibody, or epitope binding fragment thereof, according to claim 1 ,
comprising:
(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:32;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:8.

5. The monoclonal antibody, or epitope binding fragment thereof, according to claim 4 , comprising:
(a) a Light Chain comprising the amino acid sequence of SEQ ID NO:17; and
(b) a Heavy Chain comprising the amino acid sequence of SEQ ID NO:11.

6. The monoclonal antibody, or epitope binding fragment thereof, according to claim 1 , comprising:
(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:33;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:8.

7. The monoclonal antibody, or epitope binding fragment thereof, according to claim 6 , comprising:
(a) a Light Chain comprising the amino acid sequence of SEQ ID NO:18; and
(b) a Heavy Chain comprising the amino acid sequence of SEQ ID NO:11.

8. The monoclonal antibody, or epitope binding fragment thereof, according to claim 1 , comprising:
(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:34;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:8.

9. The monoclonal antibody, or epitope binding fragment thereof, according to claim 8 , comprising:
(a) a Light Chain comprising the amino acid sequence of SEQ ID NO:19; and
(b) a Heavy Chain comprising the amino acid sequence of SEQ ID NO:11.

10. A monoclonal antibody, or an epitope-binding fragment thereof, comprising:
(a) a Light Chain selected from the group consisting of SEQ ID NO:12; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22 and SEQ ID NO:23; and
(b) a Heavy Chain selected from the group consisting of SEQ ID NO:11; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; and SEQ ID NO:27.

11. A pharmaceutical composition comprising the monoclonal antibody, or epitope binding fragment thereof, according to claim 1 and a pharmaceutical acceptable carrier.

12. A method for the treatment of a tauopathy, which comprises administering a therapeutically effective amount of the monoclonal antibody, or epitope-binding fragment thereof, according to claim 1 to a subject in need thereof, wherein said tauopathy is selected from the group consisting of Alzheimer's disease, Argyrophilic Grain Disease (AGD), Psychosis, Psychosis due to AD or Psychosis in patients with AD, apathy due to AD or apathy in patients with AD, psychiatric symptoms of patients with Lewy body dementia, Progressive Supranuclear Palsy (PSP), Frontotemporal dementia (FTD or variants thereof), TBI (traumatic brain injury, acute or chronic), Corticobasal Degeneration (CBD), Picks Disease, Primary age-related tauopathy (PART), Neurofibrillary tangle-predominant senile dementia, Dementia pugilistica, Chronic traumatic encephalopathy, stroke, neurodegeneration in relation to Parkinson's disease, Parkinsonism linked to chromosome, Lytico-Bodig disease (Parkinson-dementia complex of Guam), Ganglioglioma and gangliocytoma, Meningioangiomatosis, Postencephalitic parkinsonism, Subacute sclerosing panencephalitis, Huntington's disease, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz disease and lipofuscinosis.

13. The method according to claim 12 , wherein the treatment is chronic.

14. A method for the treatment of Alzheimer's disease which comprises administering a therapeutically effective amount of the monoclonal antibody, or epitope-binding fragment thereof, according to claim 1 to a subject in need thereof.

15. A method of diagnosing or imaging Alzheimer's disease or other tauopathies in a subject, said method comprising administering to said subject a detectably labelled monoclonal antibody, or epitope-binding fragment thereof, according to claim 1 .

Assignees

• H Lundbeck As

Inventors

• Pedersen Jan Torleif
• Kjaergaard Kristian
• Pedersen Lars Østergaard
• Asuni Ayodeji Abdur-Rasheed
• Rosenqvist Nina Helen
• Daechsel Justus Claus Alfred
• Juhl Karsten
• Tagmose Lena
• Marigo Mauro
• Jensen Thomas
• Christensen Søren
• David Laurent
• Volbracht Christiane
• Helboe Lone

Classifications

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/75

  Agonist effect on antigen · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title